Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Lyndra Inc.
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05251376CT.gov Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy | — | Withdrawn | — | — | — |
NCT01595867CT.gov Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Opiate Dependence
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nepenthe (this asset) | Lyndra Inc. | P1 | CC · 47 |
| Buprenorphine | Erin Winstanley | P4 | BBB |
| 17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE | University of California, San Francisco | P4 | BB |
| Lidocaine | University Medical Centre Ljubljana | P4 | BB |
| Marcaine | Denver Health and Hospital Authority | P4 | BB |
| Gabapentin | Brigham and Women's Hospital | P4 | BB |
| Epclusa | Saskatchewan Health Authority - Regina Area | P4 | BB |
| Sufentanyl | West Virginia University | P4 | BB |
| Genvoya | Saskatchewan Health Authority - Regina Area | P4 | BB |
+20 more in the Opiate Dependence cohort
Other indications for Nepenthe
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer Of Unknown Primary Site | — | P4 | BBB · 75 |
| Chronic Pain Syndrome | — | P4 | BBB · 74 |
| Post-Operative Pain, Non-Human Animal | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nepenthe in Opiate Dependence. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nepenthe-opiate-dependence
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →